ISPOR - Estimating The Number of Relapsed And Refractory Indolent Lymphoma Patients Across Europe, Who Are Expected To Initiate A New Line of Therapy (LOT)

Full Text

Estimating The Number of Relapsed And Refractory Indolent Lymphoma Patients Across Europe, Who Are Expected To Initiate A New Line of Therapy (LOT)

Abstract

Authors

H Ellis C Neves A Chapman D Jeyakumaran

Back to Volume 20, Issue 9

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now